Stock Events

Stock Events

ProMIS Neurosciences 

$15.27
22
+$0.29+1.94% 12:08 Today

Statistics

Day High
14.97
Day Low
14.85
52W High
27.4
52W Low
6.27
Volume
1,464
Avg. Volume
-
Mkt Cap
134.34M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-7.25
-4.73
-2.21
0.31
Expected EPS
-1.231429
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-39.72MNet Income

Analyst Ratings

42.50Average Price Target
The highest estimate is 100.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PMN. It's not an investment recommendation.
NVIDIA
5
NVDA
Coca-Cola
4
KO
Quantum Computing
4
QUBT
Apple
3
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen is a direct competitor in the Alzheimer's disease treatment market, focusing on advanced biologics and therapies similar to ProMIS Neurosciences.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly is a competitor because of its significant investments in Alzheimer's disease research and development of related therapeutics, competing in the same space as ProMIS.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has been involved in the development of treatments for neurological disorders, including Alzheimer's, making it a competitor in the neurodegenerative disease sector.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. competes in the Alzheimer's disease treatment market with its research and development efforts in neurodegenerative diseases.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie is involved in neuroscience and specifically Alzheimer's disease research, making it a competitor in the development of neurodegenerative disease treatments.
Novartis
NVS
Mkt Cap286.78B
Novartis AG is a competitor due to its extensive research and development in neurodegenerative diseases, including Alzheimer's disease.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.87B
ACADIA Pharmaceuticals focuses on the central nervous system disorders, including Alzheimer's, making it a competitor in the neuroscience field.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals, with its focus on RNA-targeted drug discovery and development, competes in the development of treatments for neurodegenerative diseases like Alzheimer's.

About

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
Show more...
CEO
Neil K. Warma
Employees
11
Country
Canada
ISIN
CA74346M5054
WKN
000A41MFQ

Listings

STU
DE
23J.STU
STU
DE
23J0.STU
F
DE
23J.F
BOATS
BOATS
PMN.BOATS

0 Comments

Share your thoughts

FAQ

What is ProMIS Neurosciences stock price today?▼
The current price of PMN is $15.27 USD — it has increased by +1.94% in the past 24 hours. Watch ProMIS Neurosciences stock price performance more closely on the chart.
What is ProMIS Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange ProMIS Neurosciences stocks are traded under the ticker PMN.
Is ProMIS Neurosciences stock price growing?▼
PMN stock has risen by +3.31% compared to the previous week, the month change is a -1.38% fall, over the last year ProMIS Neurosciences has showed a +7% increase.
What is ProMIS Neurosciences market cap?▼
Today ProMIS Neurosciences has the market capitalization of 134.34M
When is the next ProMIS Neurosciences earnings date?▼
ProMIS Neurosciences is going to release the next earnings report on November 18, 2026.
What were ProMIS Neurosciences earnings last quarter?▼
PMN earnings for the last quarter are -1.28 USD per share, whereas the estimation was -1.38 USD resulting in a +7.15% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ProMIS Neurosciences revenue for the last year?▼
ProMIS Neurosciences revenue for the last year amounts to 0 USD.
What is ProMIS Neurosciences net income for the last year?▼
PMN net income for the last year is -39.72M USD.
How many employees does ProMIS Neurosciences have?▼
As of August 19, 2026, the company has 11 employees.
In which sector is ProMIS Neurosciences located?▼
ProMIS Neurosciences operates in the Health & Wellness sector.
When did ProMIS Neurosciences complete a stock split?▼
The last stock split for ProMIS Neurosciences was on November 28, 2025 with a ratio of 1:25.
Where is ProMIS Neurosciences headquartered?▼
ProMIS Neurosciences is headquartered in TORONTO, Canada.